FIELD: biotechnology.
SUBSTANCE: disclosed are bispecific antibodies which recognize FIX and/or FIXa and FX, and methods for preparing them.
EFFECT: antibodies include amino acid substitutions in the CDR sequences of the light or heavy chain, which increase the substitute function of the cofactor FVIII activity of the antibody compared to ACE910 (emicizumab).
6 cl, 2 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| METHOD FOR MEASURING REACTIVITY OF FVIII | 2015 |
|
RU2752595C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| VERSIONS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY | 2018 |
|
RU2813990C2 |
| ANTIBODY CONTAINING PREPARATION | 2017 |
|
RU2748046C2 |
| ANTIBODIES DIRECTED AGAINST Fc-RECEPTOR-LIKE PROTEIN 5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2774158C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
